What is past is prologue: Estrogen/progestin replacement tomorrow

Gynecological Endocrinology

Volumn 15, Issue SUPPL. 4, 2001, Pages 68-90

  Oettel, M ^a   Elger, W ^b   Graser T ^a   Holz, C ^a   Lahteenmaki P ^c   Patchev, V ^a  

^a BAYER PHARMA AG   (Germany)

^b EnTeC GmbH Hamburg Jena   (Germany)

^c Oy Leiras Finland Ab   (Finland)

Author keywords

17 Estradiol; Estrogen sulfamates; Hormone replacement; Hybrid progestins; Non masculinizing androgen; Phytoestrogens; Selective estrogen receptor modulators; Selective progesterone receptor modulators

Indexed keywords

EID: 0012744756     PISSN: 09513590     EISSN: None     Source Type: Journal    
DOI: 10.1080/714052692     Document Type: Article

References (164)

1. European Institute of Women's Health. Gender Mainstreaming in EU Public Health. Dublin: European Institute of Women's Health, 2000:1-10
2. Purdie DW. Consequences of long-term hormone replacement therapy. Br Med Bull 2000;56: 809-23
3. Tsang TSM, Barnes ME, Gersh BJ, Hayes SN. Risks of coronary heart disease in women: current understanding and evolving concepts. Mayo Clin Proc 2000;75:1289-303
4. Pilon D, Castilloux A-M, Lelorier J. Estrogen replacement therapy: determinants of persistence with treatment. Obstet Cynecol 2001;97:97-100
5. Shackelford DP, Lalikos JF. Estrogen replacement therapy and the surgeon. Am J Surg 2000; 179:333-6
6. Brett KM, Makans JH. Use of postmenopausal hormone replacement. Am J Epidemiol 1997;145: 536-45
7. Siiteri PK, MacDonald PC. Role of extraglandular estrogens in human endocrinology. In Geiger SR, Astwood EB, Creep RO, eds. Handbook of Physiology, vol 2. Bethesda, MD: American Physiological Society, 1973:615-29
8. Judd HL, Shamonki IM, Frumar AM, Lagasse LD. Origin of serum estradiol in postmenopausal women. Obstet Gynecol 1982;59:680-6
9. Lauritzen C. History of estrogen research. In Oettel M, Schillinger E, eds. Handbook of Experimental Pharmacology, vol 135/I, Estrogens and Antiestrogens I. Berlin: Springer, 1999:1-14
10. Inhoffen HH, Hohlweg W. Neue per os wirksame weibliche Keimdrüsenhormonderivate: 17-Aethinyl-oestradiol und Pregnenin-on-3-ol-17. Naturwissenschaften 1938;26: 96-101
11. Allen WM, Corner GW. Physiology of corpus luteum. VII. Maintenance of pregnancy in rabbit after very early castration, by corpus luteum extracts. Proc Soc Exp Biol (NY) 1930;27:403-10
12. Clauberg C. Zur Physiologie und Pathologie der Sexualhormone, im besonderen des Hormons des Corpus luteum. I. Mitt. Der biologische Test für das Luteohormon am infantilen Kaninchen. Zbl Gynäkol 1930;54:2757-61
13. Butenandt A, Westphal U, Hohlweg W. Über das Hormon des Corpus luteum. Physiol Chem 1934;227:84-90
14. Allen WM, Wintersteiner O. Crystalline progestin. Science 1934;80:190-4
15. Slotta KH, Ruschig H, Fels E. Reindarstellung der Hormone aus dem Corpus luteum. Ber Dtsch Chem Ges 1934;67:1270-5
16. Hartmann M, Wettstein A. Ein kristallisiertes Hormon aus Corpus luteum. Helv Chim Acta 1934;17:878-82
17. Andersson K, Mattson LO, Rybo G, Stadberg E. Intrauterine release of levonorgestrel - a new way of adding progestogen on hormone replacement therapy. Obstet Gynecol 1992;79:963-7
18. Luukkainen T. The levonorgestrel intrauterine system: therapeutic aspects. Steroids 2000;65: 699-702
19. Nilsson CG, Haukkamaa M, Vierola H, Luukkainen T. Tissue concentrations of levonorgestrel in women using levonorgestrel-releasing IUD. Clin Endocrinol 1982;17:529-36
20. Nilsson CG, Luukkainen T, Arko H. Endometrial morphology of women using a d-norgestrel-releasing intrauterine device. Fertil Steril 1978;29:397-401
21. Lähteenmäki P, Rauramo I, Backman T. The levonorgestrel intrauterine system in contraception. Steroids 2000;65:693-7
22. Raudaskoski TH, Lahti EI, Kauppila AJ, Apaja-Sarkkinen MA, Laatikainen TJ. Transdermal estrogen with a levonorgestrel-releasing intrauterine device for climacteric complaints: clinical and endometrial responses. Am J Obstet Gynecol 1995;172:114-19
23. Suhonen S, Allonen H, Lähteenmäki P. Sustained-release estradiol implants and a levonorgestrel-releasing intrauterine device in hormone replacement therapy. Am J Obstet Gynecol 1995;172:562-7
24. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics. CA Cancer J Clin 1996;65:5-27
25. Messina MJ, Persky V, Setchell KDR, Barnes S. Soy intake and cancer risk: a review of the in vitro and in vivo data. Nutr Cancer 1994;21:113-31
26. Tamura Y, Hirai A, Terano T, Yoshida S. Clinical and epidemiological studies of ω-3 polyunsaturated fatty acids in Japan. In Tanaka T, Okada A, eds. Nutritional Support in Organ Failure. New York: Excerpta Medica, 1990:89-95
27. Barnes S. Effect of genistein on in vitro and in vivo models of cancer. J Nutr 1995;125:777-83S
28. Ho SC, Woo JLF, Leung SSF, Sham ALK, Lam TH, Janus ED. Intake of soy products is associated with better plasma lipid profiles in the Hong Kong Chinese population. J Nutr 2000;130: 2590-3
29. Somekawa Y, Chiguchi M, Ishibashi T, Aso T. Soy intake related to menopausal symptoms, serum lipids, and bone mineral density in postmenopausal Japanese women. Obstet Gynecol 2001;97:109-15
30. Nakagawa H, Yamamoto D, Kiyozuka Y, et al. Effects of genistein and synergistic action in combination with eicosapentaenoic acid on the growth of breast cancer cell lines. J Cancer Res Clin Oncol 2000;126:448-54
31. Mazur W, Adlercreutz H. Overview of naturally occurring endocrine-active substances in the human diet in relation to human health. Nutrition 2000;16:654-87
32. Nikov GI, Hopkins NE, Boue S, Alwort WL. Interactions of dietary estrogens with human estrogen receptors and the effect of estrogen receptor-estrogen response element complex formation. Environ Health Perspect 2000;108: 867-72
33. Dubey RK, Gillespie DG, Imthum B, Rosselli M, Jackson EK, Keller PJ. Phytoestrogens inhibit growth and MAP kinase activity in human aortic smooth muscle cells. Hypertension 1999;33: 177-82
34. Wiseman H. The therapeutic potential of phytoestrogens. Exp Opin Invest Drugs 2000;9:1829-40
35. Burger HG. Selective oestrogen receptor modulators. Horm Res 2000;53(Suppl 3):25-9
36. Johnston CC and the Raloxifene Study Group. Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women. Arch Intern Med 2000;160:3444-50
37. Clemett D, Spencer CM. Raloxifene - a review of its use in postmenopausal osteoporosis. Drugs 2000;60:379-411
38. Yang NN, Venugopalan M, Hardikar S. Identification of an estrogen response element activated by metabolites of 17-beta-estradiol and raloxifene. Science 1996;273:1222-5
39. Nuttall ME, Stroup GB, Fisher PW, Nadeau DP, Gowen M, Suva LJ. Distinct mechanisms of action of selective estrogen receptor modulators in breast and osteoblastic cells. Am J Physiol Cell Physiol 2000;279:C1550-7
40. Gize EA, Venugopalan M, Glasebrook AL. Characterization of raloxifene binding and transactivation properties of the estrogen receptor-beta (ERβ) (abstr S428). J Bone Miner Res 1997;Suppl 12:5460
41. Dutertre M, Smith CL. Molecular mechanisms of selective estrogen receptor modulator (SERM) action. J Pharmacol Exp Ther 2000;295:431-7
42. Katzenellenbogen BS, Choi I, Delage-Mourroux R, et al. Molecular mechanisms of estrogen action: selective ligands and receptor pharmacology. J Steroid Biochem Mol Biol 2000;74:279-85
43. Dardes RC, Jordan VC. Novel agents to modulate oestrogen action. Br Med Bull 2000;56: 773-86
44. Osborne CK, Zhao HH, Fuqua SAW. Selective estrogen receptor modulators: structure, function, and clinical use. J Clin Oncol 2000;18: 3172-86
45. Levenson AS, Catherino WH, Jordan VG. Estrogenic activity is increased for an antiestrogen by a natural mutation of the estrogen receptor. J Steroid Biochem Mol Biol 1997;60:261-8
46. Cyr M, Calon F, Morisette M, Grandbois M, Callier S, DiPaolo T. Drugs with estrogen-like potency and brain activity: potential therapeutic applications for the CNS. Curr Pharm Design 2000;6:1287-312
47. Verghese J, Kuslansky G, Katz MJ, et al. Cognitive performance in surgically menopausal women on estrogen. Neurology 2000;55:872-4
48. Jones KP. Menopause and cognitive function: estrogens and alternative therapies. Clin Obstet Gynecol 2000;43:198-206
49. Hogervorst E, Williams J, Budge M, Riedel W, Jolles J. The nature of the effect of female gonadal hormone replacement therapy on cognitive function in postmenopausal women: a meta-analysis. Neuroscience 2000;101:485-512
50. Paganini-Hill A, Henderson VW. Estrogen deficiency and risk of Alzheimer's disease in women. Am J Epidemiol 1994;140:256-63
51. Leranth C, Roth RH, Elswoth JD, Naftolin F, Horvath TL, Redmond DE. Estrogen is essential for maintaining nigostrial dopamine neurons in primates: implications for Parkinson's disease and memory. J Neurosci 2000;20:8604-9
52. Green PS, Yang S-H, Nilsson KR, Kumar AS, Covey DF, Simpkins JW. The nonfeminizing enantiomer of 17β-estradiol exerts protective effects in neuronal cultures and a rat model of cerebral ischemia. Endocrinology 2001;142:400-6
53. Neuwinger J, Esper J, Mück I, Wildt L. Biological effects of 17α-estradiol in hypogonadal women. Acta Endocrinol 1992;126(Suppl 4):83
54. Berlau J, Roemer W, Oettel M, Hipler UC, Patchev V, Schreiber G. 17α-oestradiol and 17β-oestradiol do not affect basal and follicle-stimulating hormone-stimulated inhibin B secretion by highly purified rat Sertoli cells. Andrologia 2000;32:345-9
55. Schröder J, Dören M, Schneider B, Oettel M. Are the antioxidative effects of 17β-estradiol modified by concomitant administration of a progestin? Maturitas 1996;25:133-9
56. 8,9-dehydro derivatives of 17α-estradiol and 17β-estradiol. Steroids 1997;62: 304-10
57. Oettel M, Römer W, Heller R. The therapeutic potential of scavestrogens. Eur J Obstet Gynecol 1996;65:1253
58. Blum-Degen D, Haas M, Pohli S, et al. Scavestrogens protect IMR 32 cells from oxidative stress-induced cell death. Toxicol Appl Pharmacol 1998;152:49-55
59. Götz ME, Ahlbom E, Zhivotovsky B, et al. Radical scavenging compound J 811 inhibits hydrogen peroxide-induced death of cerebellar granule cells. J Neurosci Res 1999;56:420-6
60. Blum-Degen D, Götz ME. Novel 17α-estradiol analogues as potent radical scavengers. In Iqbal K, Swaab DF, Winblad B, Wisniewski HM, eds. Alzheimer's Disease and Related Disorders. New York: John Wiley & Sons, 1999
61. Daré E, Götz ME, Zhivotovsky B, Manzo L, Ceccatelli S. Antioxidants J 811 and 17β-estradiol protect cerebellar granule cells from methylmercury-induced apoptotic cell death. J Neurosci Res 2000;62:557-65
62. Buko V, Lukivskaya O, Naruta E, et al. Radical-scavenging and antiatherogenic effects of scav-estrogens in cholesterol-fed rabbits. Fund Clin Pharmacol 1999;13(Suppl 1):PM 167
63. Zhi L, Tegley CM, Edwards JP, et al. 5-Alkyl 1,2-dihydrochromenol[3,4-f]quinolines: a novel class of nonsteroidal progesterone receptor modulators. Bioorg Med Chem Lett 1998;8: 3365-70
64. Meda C, Vegeto E, Pollio G, et al. Oestrogen prevention of neuronal cell death correlates with decreased expression of mRNAQ for the proapoptotic protein Nip-2. J Neuroendocrinol 2000; 12:1051-9
65. Patchev V, Römer W, Schwarz S, et al. Non-feminizing radical-scavenging estrogens: evidence for selective neurotropic action in vivo and implications in neuroprotection. Xth International Congress on Hormonal Steroids, Québec City, June 17-21, 1998:198
66. Oettel M. Estrogens and antiestrogens in the male. In Oettel M, Schillinger E, eds. Handbook of Experimental Pharmacology, vol 135/II, Estrogens and Antiestrogens II. Berlin: Springer-Verlag, 1999:505-71
67. Simpson ER, Davis SR. Another role highlighted for estrogens in the male: sexual behavior. Proc Nat Acad Sci 2000;97:14038-40
68. Van den Beld AW, Lamberts SWJ. The male climacterium: clinical signs and symptoms of a changing endocrine environment. Prostate 2000; 10(Suppl):2-8
69. Järvinen A, Nykänen S, Paasiniemi L. Absorption and bioavailability of oestradiol from a gel, a patch and a tablet. Maturitas 1999;32:103-13
70. Scott RT, Ross B, Anderson C, Archer DF. Pharmacokinetics of percutaneous estradiol: a crossover study using a gel and a transdermal system in comparison with oral micronized estradiol. Obstet Gynecol 1991;77:758-64
71. Simon JA, Hodgen GD, Archer DF. Are there any significant pharmacokinetic differences between patch and gel cutaneous estradiol therapy? In Genazzani AR, Petraglia F, Volpe A, Fachinetti F, eds. Recent Research on Gynecological Endocrinology, vol 2. Carnforth, UK: Parthenon Publishing, 1988:317-24
72. Scott RT, Ross B, Anderson C, Archer DF. Pharmacokinetics of percutaneous estradiol: a crossover study using a gel and a transdermal system in comparison with oral micronized estradiol. Obstet Gynecol 1991;77:758-64
73. Järvinen A, Nykänen S, Paasiniemi L. Absorption and bioavailability of oestradiol from a gel, a patch and a tablet. Maturitas 1999;32:103-13
74. Hoibraaten E, Qvigstad E, Arnesen H, Larsen S, Wickstrom E, Sandset PM. Increased risk of recurrent venous thromboembolism during hormone replacement therapy. Thromb Haemost 2000;84:961-7
75. Schwarz S, Weber G, Kühner F. Sulfamate des 17αÄthinylestradiols. Z Chem 1970;10:299-300
76. Stölzner W. Tierexperimenteller Beitrag zur Entwicklung estrogener Wirkstoffe. Dissertation (Promotion B), Friedrich-Schiller Universität Jena, 1989
77. Elger W, Schwarz S, Hedden A, Reddersen G, Schneider B. Sulfamates of various estrogens are prodrugs with increased systemic and reduced hepatic estrogenicity at oral application. J Steroid Biochem Mol Biol 1995;55:395-403
78. Schwarz S, Elger W. Estrogen sulfamates, a novel approach to oral contraception and hormone replacement therapy. Drugs Future 1996;21:49-61
79. Elger W, Palme HJ, Schwarz S. Novel oestrogen sulfamates: a new approach to oral hormone therapy. Exp Opin Invest Drugs 1998;7:575-89
80. Lippert TH, Seeger H, Mück AO. The impact of endogenous estradiol metabolites on carcinogenesis. Steroids 2000;65:357-69
81. Clemons M, Goss P. Estrogen and the risk of breast cancer. N Engl J Med 2001;344:276-85
82. Singh A, Purohit A, Hejaz HAM, Potter BVL, Reed MJ. Inhibition of deoxyglucose uptake in MCF-7 breast cancer cells by 2-methoxyestrone and 2-methoxyestrone-3-O-sulfamate. Mol Cell Endocrinol 2000;160:61-6
83. MacCarthy-Morrogh L, Townsed PA, Purohit A, et al. Differential effects of estrone and estrone-3-O-sulfamate derivatives on mitotic arrest, apoptosis, and microtubule assembly in human breast cancer cells. Cancer Res 2000;60: 5441-50
84. Purohit A, Dauvois S, Parker MG, Potter BVL, Williams GJ, Reed MJ. The hydrolysis of oestrone sulphate and dehydroepiandrosterone sulphate by human steroid sulphatase expressed in transfected COS-1 cells. J Steroid Biochem Mol Biol 1994;50:101-4
85. Howarth NM, Purohit A, Reed MJ, Potter BVL. Estrone sulfamates: potent inhibitors of estrone sulfatase with therapeutic potential. J Med Chem 1994;37:219-21
86. Purohit A, Williams GJ, Howarth NM, Potter BVL, Reed MJ. Inactivation of steroid sulfatase by an active site-directed inhibitor, estrone-3-O-sulfamate. Biochemistry 1995;34:11508-14
87. Purohit A, Williams GJ, Roberts CJ, Potter BVL, Reed MJ. In vivo inhibition of oestrone sulphatase and dehydroepiandrosterone sulphatase by oestrone-3-O-sulphamate. Int J Cancer 1995;63: 106-11
88. Reed MJ, Purohit A, Duncan LJ, et al. The role of cytokines and sulphatase inhibitors in regulating oestrogen synthesis in breast tumours. J Steroid Biochem Mol Biol 1995;53:413-20
89. Loo LWL, Lightowler M, Purohit A, Reed MJ, Potter BVL. Heteroatom-substituted analogues of the active-site directed inhibitor estra-1,3,5 (10)-trien-17-one-3-sulphamate inhibit estrone sulphatase by a different mechanism. J Steroid Biochem Mol Biol 1996;57:79-88
90. Selcer KW, Jagannathan S, Rhodes ME, Li PK. Inhibition of placental estrone sulfatase activity and MCF-7 breast cancer cell proliferation by estrone-3-amino derivatives. J Steroid Biochem Mol Biol 1996;59:83-91
91. Purohit A, Froome VA, Wang DY, Potter BVL, Reed MJ. Measurement of oestrone sulphatase activity in white blood cells to monitor in vivo inhibition of steroid sulphatase activity by oestrone-3-O-sulphamate. J Steroid Biochem Mol Biol 1997;62:45-51
92. Howarth NM, Purohit A, Reed MJ, Potter BVL. Estrone sulfonates as inhibitors of estrone sulfatase. Steroids 1997;62:346-50
93. Woo LWL, Howarth NM, Purohit A, Hejaz HAM, Reed MJ, Potter BVL. Steroidal and nonsteroidal sulfamates as potent inhibitors of steroid sulfatase. J Med Chem 1998;41:1068-83
94. Römer W, Oettel M, Schwarz S. Scavestrogen sulfamates: correlation between estrone sulfatase inhibiting and antioxidant effects. Can J Physiol Pharmacol 1998;76:99-109
95. Ciobanu LC, Boivin RP, Van Luu-The, Labrie F, Poirier D. Potent inhibition of steroid sulfatase activity by 3-O-sulfamate 17α-benzyl (or 4′-tert-butylbenzyl) estra-1,3,5(10)-trienes: combination of two substituents at positions C3 and C17α of estradiol. J Med Chem 1999;42:2280-6
96. Hejaz HAM, Purohit A, Mahon MF, Reed MJ, Potter BVL. Synthesis and biological activity of the superestrogen (E)-17-oximino-3-O-sulfamoyl-1,3,5(10)-estratriene: X-ray crystal structure of (E)-17-oximino-3-hydroxy-1,3,5 (10)-etratriene. J Med Chem 1999;42:3188-92
97. Valigora SD, Li KP, Dunphy G, Turner M, Ely DL. Steroid sulfatase inhibitor alters blood pressure and steroid profiles in hypertensive rats. J Steroid Biochem Mol Biol 2000;73:113-22
98. Barth A, Römer W, Oettel M. Influence of subchronic administration of oestrone-3-O-sulphamate on oestrone sulphatase activity in liver, spleen and white blood cells of ovariectomized rats. Arch Toxicol 2000;74:366-71
99. Li PK, Rhodes ME, Jagannathan S, Johnson DA. Reversal of scopolamine induced amnesia in rats by the steroid sulfatase inhibitor estrone-3-O-sulfamate. Cogn Brain Res 1995;2:251-4
100. Flood JF, Farr SA, Johnson DA, Li PK, Morley JE. Peripheral steroid sulfatase inhibition potentiates improvement of memory retention for hippocampally administered dehydroepiandrosterone sulfate but not pregnenolone sulfate. Psychoneuroendocrinology 1999;24:799-811
101. Nedvidkova J, Haluzik M, Pacak K, Schreiber V, Starka L. Estrogenic effects of estradiol-sulfamate on the male rat anterior pituitary. J Steroid Biochem Mol Biol 1998;67:359-62
102. Aragones MIH, Purohit A, Parish D, Sahm UG. Pouton CW, Potter BVL, Reed MJ. Pharmacokinetics of oestrone-3-O-sulphamate. J Steroid Biochem Mol Biol 1996;58:611-17
103. Zimmermann H, Elger W, Oettel M. Comparative toxicology of ethinylestradiol (EE) and a new estrogen without 17-alpha ethinyl group: 17-beta-estradiol-3-sulfamate (J 995). Toxicol Lett 1996;88(Suppl):100
104. Barth A, Elger W, Schneider B, Schwarz S. Influence of subchronic administration of oestradiol, ethinyloestradiol and oestradiol sulphamate on bile flow, bile acid excretion, and liver and biliary glutathione status in rats. Arch Toxicol 1997;71: 443-9
105. Elger W, Palme HJ, Schwarz S. Novel oestrogen sulfamates: a new approach to oral hormone therapy. Exp Opin Invest Drugs 1998;7:575-89
106. Hoffmann H, Moore C, Zimmermann H, et al. Approaches to the replacement of ethinylestradiol by natural 17β-estradiol in combined oral contraceptives. Exp Toxic Pathol 1998;50:458-64
107. Gruber DM, Wieser F, Sator M, Gruber JC. Die Bedeutung des Progesterons und der Gestagene im Klimakterium. Zbl Gynäkol 1997;119:34-7
108. Kuhl H. Comparative pharmacology of newer progestogens. Drugs 1996;51:188-215
109. Sitruk-Ware R. Progestins and cardiovascular risk markers. Steroids 2000;65:651-8
110. Campagnoli C, Belforte P, DiSario MM, Lesca L. Lipid profile during hormone replacement therapy: effect of different progestins? Zbl Gynäkol 1997;119:1-6
111. Oettel M, Holz C. Hybrid progestins: the example of dienogest. In Sitruk-Ware R, Mishell DR, eds. Progestins and Antiprogestins in Clinical Practice. New York: Marcel Dekker, 2000: 163-78
112. Krattenmacher R. Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception 2000;62:29-38
113. Philibert D, Bouchoux F, Degryse M, Lecaque D, Petit F, Gaillard M. The pharmacological profile of a novel norpregnane progestin (trimegestone). Gynecol Endocrinol 1999;13:316-26
114. Sorbera LA, Leeson PA, Castaner J. Trimegestone. Drugs Future 2000;25:465-73
115. Paris JM, Williams KJ, Hermsmeyer KR, Delansorne R. Nomegestrol acetate and vascular reactivity: nonhuman primate experiments. Steroids 2000;65:621-7
116. ®: a progestin with a unique pharmacological profile. Steroids 2000;65:629-36
117. Oettel M, Graeser T, Hoffmann H, Moore C, Zimmermann H, Zimmermann T. The preclinical profile of dienogest. A short overview. Drugs Today 1999;35(Suppl C):3-12
118. Katsuki Y, Hirano K. Mechanism of action of dienogest, a synthetic steroid. Gifu Yakka Daigaku Kiyo 1999;48:33-42
119. Oettel M, Bervoas-Martin S, Elger W, et al. A 19-norprogestin without 17α-ethinyl group I: dienogest from a pharmacokinetic point of view. Drugs Today 1995;31:499-516
120. Oettel M, Carol W, Elger W, et al. A 19-norprogestin without 17α-ethinyl group II: dienogest from a pharmacodynamic point of view. Drugs Today 1995;31:517-36
121. Schneider B, Elger W, Ernst M. Assessment of gestagen effects on bone metabolism in the rat. Exp Clin Endocrinol 1993;101(Suppl 1):71
122. Shibutani Y, Futamura Y, Katsuki Y. Bone-resorptive cytokine inhibitor containing dienogest as the active ingredient. European Patent Application EP 1 043 331 A1, 2000
123. HaywoodL, Kasperk CH, Wakley GK. Progestin and androgen co-therapy prevents loss of cancellous bone mass after ovarian hormone depletion. 2001;in press
124. Oettel M, Bocker T, Güttner J, Horn M, Stölzner W. Studie zur Entwicklung eines geeigneten Modells zur Endometriosis externa bei Kaninchen und Ratten und die Effekte von Dienogest und Danazol. Fertilität 1992;8:134-5
125. Moore C, Carol W, Gräser T, Mellinger U, Walter F. Influence of dienogest on ovulation in young fertile women. Clin Drug Invest 1999;18: 271-8
126. Katsuki Y, Takano Y, Futamura Y, et al. Effects of dienogest, a synthetic steroid, on experimental endometriosis in rats. Eur J Endocrinol 1998;138: 216-26
127. Gräser T, Müller A, Mellinger U, Mück AO, Lippert TH, Oettel M. Continuous-combined treatment of the menopause with combinations of oestradiol valerate and dienogest - a dose-ranging study. Maturitas 2000;35:253-61
128. Hammarbäck S, Bäckström T, Holst J, von Schoultz B, Lyrenäs S. Cyclical mood changes as in the premenstrual tension syndrome during sequential estrogen-progestogen postenopausal replacement therapy. Acta Obstet Gynecol Scand 1985;64:393-7
129. Magos AL, Brewster E, Sing R, O'Dowd TM, Studd JWW. The effect of norethisterone in postmenopausal women on oestrogen therapy: a model for the premenstrual syndrome. Br J Obstet Gynaecol 1986;93:1290-6
130. Panay N, Studd J. Progestogen intolerance and compliance with hormone replacement therapy in menopausal women. Hum Reprod Update 1997;3:159-71
131. Björn I, Bixo M, Strandberg K, Nyberg S, Bäckström T. Negative mood changes during hormone replacement therapy: a comparison between two progestogens. Am J Obstet Gynecol 2000;183:1419-26
132. Zweifel JE, O'Brian WH. A meta-analysis of the effect of hormone replacement therapy upon depressed mood. Psychoneuroendocrinology 1997; 22:189-212
133. Sherwin BB. The impact of different doses of estrogen and progestin on mood and sexual behaviour in postmenopausal women. J Clin Endocrinol Metab 1991;72:336-43
134. Persson I. Estrogens in the causation of breast, endometrial and ovarian cancers - evidence and hypotheses from epidemiological findings. J Steroid Biochem Mol Biol 2000;74:357-64
135. Santen RJ, Pinkerton J, McCartney C, Petroni GR. Risk of breast cancer with progestins in combination with estrogen as hormone replacement therapy. J Clin Endocrinol Metab 2001;86: 16-23
136. Katsuki Y, Shibutani Y, Aoki D, Nozawa S. Dienogest, a novel synthetic steroid, overcomes hormone-dependent cancer in a different manner than progestins. Cancer 1997;79:169-76
137. Futamara Y, Nakamura M. Neovascularization inhibitor containing dienogest as the active ingredient. European Patent Application EP 1 048 673 A1, 2000
138. Ishikawa T, Inoue S, Kakinuma C, Kuwayama C, Hamada Y, Shibutani Y. Growth-stimulating effect of dienogest, a synthetic steroid, on rodent, canine, and primate mammary glands. Toxicology 2000;151:91-101
139. Kam GYW, Leung K-C, Baxter RC, Ho KKY. Estrogens exert route- and dose-dependent effects on insulin-like growth factor (IGF)-binding protein-3 and the acid-labile subunit of the IGF ternary complex. J Clin Endocrinol Metab 2000;85:1918-22
140. Cardim HJP, Lopes CMC, Giannella-Neto D, da Fonseca AM, Pinozzi JA. The insulin-like growth factor-I system and hormonal replacement therapy. Fertil Steril 2001;75:282-7
141. ® for continuous combined hormone replacement therapy in postmenopausal women. Climacteric 2000;3:109-18
142. Campagnoli C, Biglia N, Lanza MG, Lesca L, Peris C, Sismondi P. Androgenic progestogens oppose the the decrease of insulin-like growth factor I serum level induced by conjugated oestrogens in postmenopausal women. Preliminary report. Maturitas 1994;19:25-31
143. Hankinson SE, Willett WC, Colditz GA, et al. Circulating concentrations of insulin-like growth factor I and risk of breast cancer. Lancet 1998; 351:1393-6
144. Byrne C, Colditz GA, Willett WC, Speizer FE, Pollak M, Hankinson SE. Plasma insulin-like growth factor (IGF) I, IGF-binding protein 3, and mammographic density. Cancer Res 2000;60: 3744-8
145. Coelingh Bennink HJT. The Jerusalem declaration on progesterone receptor modulators. Steroids 2000;65:839
146. Mulac-Jericevic B, Mullinax RA, DeMayo FJ, Lydon JP, Conneely OM. Subgroup of reproductive functions of progesterone mediated by progesterone receptor-B isoform. Science 2000; 289:1751-4
147. Conneely OM, Lydon JP. Progesterone receptors in reproduction: functional impact of the A and B isoforms. Steroids 2000;65:571-7
148. Hirata S, Shoda T, Kato J, Hoshi K. The novel isoform of the progesterone receptor cDNA in the human testis and detection of its mRNA in the human uterine endometrium. Oncology 2000; 59(Suppl 1):39-44
149. Kloosterboer HJ, Deckers GH, Schoonen WGEJ, et al. Preclinical experience with two selective progesterone receptor modulators on breast and endometrium. Steroids 2000;65: 733-40
150. Klijn JGM, Setyono-Han B, Foekens JA. Progesterone antagonists and progesterone modulators in the treatment of breast cancer. Steroids 2000;65: 825-30
151. Wagner BL, Pollio G, Giangrande P, et al. The novel progesterone antagonists RTI 3021-012 and RTI 3021-022 exhibit complex glucocorticoid receptor antagonist activities: implications for the development of dissociated antiprogestins. Endocrinology 1999;140:1449-58
152. Jones TK, Pathirana C, Goldman ME, et al. Discovery of novel intracellular receptor modulating drugs. J Steroid Biochem Mol Biol 1996;56:61-6
153. Edwards JP, Zhi L, Pooley CLF, et al. Preparation, resolution, and biological evaluation of 5-aryl-1,2-dihydro-5H-chromeno[3,4-f]quinolines: potent, orally active, nonsteroidal progesterone receptor agonists. J Med Chem 1998;41: 2779-85
154. Dukes M, Furr BJA, Hughes LR, Tucker H, Woodburn JR. Nonsteroidal progestins and antiprogestins related to flutamide. Steroids 2000;65: 725-31
155. Elger W, Bartley J, Schneider B, Kaufmann G, Schubert G, Chwalisz K. Endocrine pharmacological characterization of progesterone antagonists and progesterone receptor modulators with respect to PR-agonistic and antagonistic activity. Steroids 2000;65:713-23
156. Chwalisz K, Brenner RM, Fuhrmann U, Hess-Stumpf H, Elger W. Antiproliferative effects of progesterone antagonists and progesterone receptor modulators on the endometrium. Steroids 2000;65:741-51
157. Elger W, Chwalisz K. Antigestagene für die gynäkologische Therapie. Reproduktionsmedizin 1999;15:318-35
158. Arlt W, Justl HG, Callies F, et al. Oral dehydroepiandrosterone for adrenal androgen replacement: pharmacokinetics and peripheral conversion to androgens and estrogens in young healthy females after dexamethasone suppression. J Clin Endocrinol Metab 1998;83:1928-34
159. Arlt W, Haas J, Callies F, et al. Biotransformation of oral dehydroepiandrosterone in elderly men: significant increase in circulating estrogens. J Clin Endocrinol Metab 1999;84:2170-6
160. Callies F, Arlt W, Siekmann L, Hübler D, Bidlingmaier F, Allolio B. Influence of oral dehydroepiandrosterone (DHEA) on urinary steroid metabolites in males and females. Steroids 2000;65:98-102
161. Arlt W, Callies F, Van Vlijmen JC, et al. Dehydroepiandrosterone replacement in women with adrenal insufficiency. N Engl J Med 1999; 341:1013-20
162. Allolio B, Arlt W. Dehydroepiandrosterone substitution in women. J Endocrinol Invest 1999;22 (Suppl 10):29-31
163. Negro-Vilar A. Selective androgen receptor modulators (SARM's): a novel approach to androgen therapy for the new millennium. J Clin Endocrinol 1999;84:3459-62
164. Müller JM, Isele U, Metzger E, et al. FHL2, a novel tissue-specific coactivator of the androgen receptor (AR). EMBO J 2000;19:359-69